Satipharm Europe Ltd

Satipharm Europe Ltd is a small, active company based in London, UK, founded eight years ago in 2016. It employs three people and holds £910,304 in assets, operating from a virtual address shared by many other companies. The company has four directors, but no owners are reported. Satipharm is an irregular importer of paper and paperboard products (one month of imports recorded) and an irregular exporter of miscellaneous food products (also one month).

The company’s website, smartercbdcapsules.com, focuses on selling CBD capsules, emphasizing their clinical trials and Gelpell technology which increases bioavailability. It caters to healthcare professionals and Canadian residents, with a strong emphasis on quality certifications and scientific validation. The site also features a blog with articles on topics like CBD for running and sleep hygiene. It’s clear Satipharm is positioning itself as a premium CBD brand with a focus on science-backed products.

Financially, Satipharm Europe Ltd presents a mixed picture. While current assets increased by 16% to £910,000, net losses deepened significantly, reaching -£750,000 – a substantial increase from the previous year’s -£40,000. Bank borrowings surged, and cash reserves dwindled, suggesting the company is burning through money. Trade debtors decreased, which is good, but creditors also increased, indicating a reliance on short-term financing. The company’s small size (meeting two of three conditions for a small company) helps with agility, but the substantial loss and increased debt are concerning. The accounts are audited, and Afford Bond Holdings Limited served as the auditor, but no senior statutory auditor was named. It’s likely that the company is facing challenges in scaling its operations and achieving profitability, despite its premium branding and scientific focus.

Registered in England/Wales under the registration number 10344288, with a registered address at EC4R 1BE, United Kingdom, London, First Floor, 10 Queen Street Place.

WARNING:The numbers have been rounded for simplicity and may be inaccurate.Please, refer to the latest financial report for verification.